HeartBeam has submitted a 510(k) application to the US Food and Drug Administration (FDA) for its 12-lead electrocardiogram ...

カリフォルニア州サンタクララ - 時価総額8,320万ドルの医療技術企業HeartBeam, Inc. (NASDAQ: BEAT)は、心臓治療の向上を目的とした革新的な心電図(ECG)システムについて、米国食品医薬品局(FDA)から510(k)承認を取得しました。InvestingProのデータによると、同社の株価 ...

市場の信頼を示す注目すべき動きとして、時価総額8,320万ドルの小型株HeartBeam Inc. (BEAT)の株価が52週高値を更新し、3.48ドルに達しました。この重要な節目は、過去1年間で149.6%の大幅な上昇を反映しており、同株は強い流動性指標を示し、ベータ値-0.84で広範 ...

HeartBeam, Inc. , a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it has submitted a 510(k) application to the U.S. Food ...

Despite a net loss and cash constraints, HeartBeam Inc (BEAT) remains optimistic about FDA clearance and its groundbreaking ECG technology. As the U.S. stock market experiences a downturn ...

HeartBeam (NASDAQ: BEAT) , a medical technology company advancing cardiac care, has submitted a 510 (k) application to the U.S. Food and Drug Administration (“FDA”) for its 12-lead electrocardiogram ( ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

Heartbeam Inc stock price live, this page displays NASDAQ BEAT stock exchange data. View the BEAT premarket stock price ahead of the market session or assess the after hours quote. Monitor the ...